Voyager Acquisition Corp

VERAXA Biotech is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones centered on its proprietary BiTAC platform. The Swiss biotechnology company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement for up to an undisclosed additional amount. VERAXA is advancing an oncology pipeline built around BiTAC, an AND-gated therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June, and recently appointed Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer.